PERISCOPE: road towards effective control of pertussis

Autor: Diavatopoulos, D.A., Mills, K.H.G., Kester, K.E., Kampmann, B., Silerova, M., Heininger, U., Dongen, J.J.M. van, Most, R.G. van der, Huijnen, M.A., Siena, E., Mielcarek, N., Ochs, M.M., Denoel, P., Berbers, G., Buisman, A.M., Jonge, M.I. de, Fenwick, C., Gorringe, A., He, Q.S., Kelly, D., Grand, R. le, Locht, C., Mascart, F., Mertsola, J., Orfao, A., Pantaleo, G., Pollard, A.J., Preston, A., Read, R., Sebo, P., Els, C. van, Vecerek, B., Londono-Hayes, P., Groot, R. de, PERISCOPE Consortium
Přispěvatelé: Radboud University Medical Center [Nijmegen], Trinity College Dublin, Sanofi Pasteur [Swiftwater, PN, USA] (Discovery Drive), Medical Research Council Unit The Gambia (MRC), London School of Hygiene and Tropical Medicine (LSHTM), GlaxoSmithKline Vaccines [Rixensart, Belgium], GlaxoSmithKline [Rixensart, Belgium], University of Basel (Unibas), Leiden University Medical Center (LUMC), Universiteit Leiden, GlaxoSmithKline [Siena, Italy] (GSK), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Sanofi Pasteur [Marcy-l'Étoile, France], National Institute for Public Health and the Environment [Bilthoven] (RIVM), Université de Lausanne = University of Lausanne (UNIL), Public Health England [London], University of Turku, University of Oxford, Immunologie des Maladies Virales et Autoimmunes (IMVA - U1184), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université libre de Bruxelles (ULB), Universidad de Salamanca, University of Bath [Bath], University Hospital Southampton NHS Foundation Trust [Southampton, UK], Czech Academy of Sciences [Prague] (CAS), Mielcarek, nathalie, Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Université de Lausanne (UNIL), University of Oxford [Oxford], Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Protective immunity
Economic growth
medicine.medical_specialty
Whooping Cough
International Cooperation
[SDV]Life Sciences [q-bio]
Drug Evaluation
Preclinical
lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]
Bordetella pertussis
03 medical and health sciences
Immunogenicity
Vaccine
0302 clinical medicine
All institutes and research themes of the Radboud University Medical Center
[SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology
Age groups
medicine
Animals
Humans
030212 general & internal medicine
Pertussis Vaccine
Licensure
Immunity
Cellular
Incidence
Public health
Vaccination
Metabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]
Infant mortality
Immunity
Humoral
3. Good health
Europe
[SDV] Life Sciences [q-bio]
030104 developmental biology
Infectious Diseases
Bibliometrics
Carrier State
Business
[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
Biomarkers
Zdroj: The Lancet Infectious Diseases
The Lancet Infectious Diseases, 2019, 19 (5), pp.e179-e186. ⟨10.1016/s1473-3099(18)30646-7⟩
Lancet Infectious Diseases, 19, 5, pp. E179-E186
The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2019, 19 (5), pp.e179-e186. ⟨10.1016/s1473-3099(18)30646-7⟩
Lancet Infectious Diseases, 19, E179-E186
The Lancet Infectious Diseases, 19(5), E179-E186. ELSEVIER SCI LTD
ISSN: 1473-3099
1474-4457
DOI: 10.1016/s1473-3099(18)30646-7
Popis: International audience; The resurgence and changing epidemiology of pertussis in high-income countries, the high infant mortality caused by pertussis in low-income countries, and the increasing morbidity in all age groups worldwide call for a concerted effort to both improve the current vaccines and develop new vaccines and vaccination strategies against pertussis. In this Personal View, we identify several key obstacles on the path to developing a durable solution for global control of pertussis. To systematically address these obstacles, the PERtussIS Correlates Of Protection Europe (PERISCOPE) Consortium was established in March, 2016. The objectives of this consortium are to increase scientific understanding of immunity to pertussis in humans induced by vaccines and infections, to identify biomarkers of protective immunity, and to generate technologies and infrastructure for the future development of improved pertussis vaccines. By working towards the accelerated licensure and implementation of novel, well tolerated, and effective pertussis vaccines, we hope to strengthen and stimulate further collaboration and transparency between the key stakeholders, including the public, the scientific community, public health institutes, regulatory authorities, and vaccine manufacturers.
Databáze: OpenAIRE
Externí odkaz: